Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)

Fig. 4

Early imaging RECIST evaluation predicts response to ICI. a Patients with RECIST responder (PR) had longer PFS than those with RECIST non-responder (SD + PD, median unreached versus 8.8 months). b Early RECIST response had good specificity, but low sensitivity to predict DCB. c Patients classified as molecular responders had longer PFS than nonmolecular responders in the cohort which RECIST were defined as SD (median 9.8 months versus 5.8 months). RECIST The response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD disease progression, PFS progression-free survival, DCB durable clinical benefit. P < 0.05 represents statistical significance

Back to article page